SCLERODERMA
Clinical trials for SCLERODERMA explained in plain language.
Never miss a new study
Get alerted when new SCLERODERMA trials appear
Sign up with your email to follow new studies for SCLERODERMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise for rare, Hard-to-Treat scleroderma
Disease control OngoingThis study tests whether anifrolumab, an injected drug, can help people with systemic sclerosis (scleroderma) — a disease that causes skin thickening and can damage organs like the lungs. About 314 adults aged 18 to 70 with early-stage disease will receive either the drug or a pl…
Matched conditions: SCLERODERMA
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
Can a brain boost program sharpen thinking in scleroderma patients?
Symptom relief OngoingThis study tests an 8-week online group program designed to help people with scleroderma improve their thinking skills and overall well-being. Researchers will compare participants who take the program right away to those on a waitlist. The goal is to see if the program boosts me…
Matched conditions: SCLERODERMA
Phase: NA • Sponsor: University of Michigan • Aim: Symptom relief
Last updated May 15, 2026 11:53 UTC
-
New ultrasound technique could improve monitoring of childhood skin disease
Knowledge-focused ENROLLING_BY_INVITATIONThis study explores whether a special ultrasound called elastography can measure changes in skin stiffness in children with localized scleroderma (morphea). About 20 kids will be followed for 9-12 months after starting treatment. The goal is to see if this painless tool can help …
Matched conditions: SCLERODERMA
Sponsor: The Hospital for Sick Children • Aim: Knowledge-focused
Last updated May 17, 2026 05:31 UTC
-
Rare disease pregnancy study withdrawn before start
Knowledge-focused TerminatedThis study was designed to track pregnancies in women with rare autoimmune diseases like lupus, arthritis, and scleroderma. The goal was to learn about complications and improve care. However, the study was withdrawn before enrolling any participants, so no results are available.
Matched conditions: SCLERODERMA
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated May 11, 2026 20:53 UTC